Incyte
INCY
$57.05
Share price
0.00%
Change (1 day)
-13.82%
Change (1 year)
Categories
Incyte (INCY) - P/B ratio
P/B ratio as of May 2024 : 2.40
According to Incyte's latest financial reports the company has a price-to-book ratio of 2.40.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Incyte - P/B ratio (from 2001 to 2024)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 2.71 | -33.69% |
| 2022-12-31 | 4.09 | -4.92% |
| 2021-12-31 | 4.30 | -41.04% |
| 2020-12-31 | 7.29 | 0.41% |
| 2019-12-31 | 7.26 | 3.17% |
| 2018-12-31 | 7.04 | -42.55% |
| 2017-12-31 | 12.3 | -72.78% |
| 2016-12-31 | 45.0 | -61.92% |
| 2015-12-31 | 118 | -177.28% |
| 2014-12-31 | -153 | 258.15% |
| 2013-12-31 | -42.7 | 237.25% |
| 2012-12-31 | -12.7 | 51.76% |
| 2011-12-31 | -8.35 | -63.75% |
| 2010-12-31 | -23.0 | 117.7% |
| 2009-12-31 | -10.6 | 534.11% |
| 2008-12-31 | -1.67 | -68.68% |
| 2007-12-31 | -5.33 | -7.79% |
| 2006-12-31 | -5.78 | -74.9% |
| 2005-12-31 | -23.0 | -317.87% |
| 2004-12-31 | 10.6 | 228.54% |
| 2003-12-31 | 3.22 | 217.4% |
| 2002-12-31 | 1.01 |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 5.30 | 120.64% | 🇨🇭 Switzerland |
 Pfizer PFE | 1.83 | -23.66% | 🇺🇸 USA |
 Eli Lilly LLY | 58.0 | 2,315.47% | 🇺🇸 USA |
 Amgen AMGN | 27.5 | 1,043.79% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 2.20 | -8.45% | 🇺🇸 USA |
 Geron GERN | 9.46 | 293.84% | 🇺🇸 USA |
 CTI BioPharma
CTIC | -47.3 | -2,069.82% | 🇺🇸 USA |
 AVEO Oncology
AVEO | 18.1 | 652.92% | 🇺🇸 USA |
 Ardelyx ARDX | 11.3 | 372.12% | 🇺🇸 USA |